Eligo | In vivo gene editing of the microbiome
Eligo Bioscience is a clinical-stage biotechnology company developing in vivo gene editing medicines that precisely target the microbiome. Their proprietary GEM (Gene Editing of the Microbiome) platform uses phage-derived delivery systems to edit bacterial genes inside the body, enabling precision treatment of diseases in oncology, inflammation, and autoimmunity driven by specific microbial gene expression.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
